Compounds > lasofoxifene
Page last updated: 2024-09-05

lasofoxifene and Atrophy

lasofoxifene has been researched along with Atrophy in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pinkerton, JV; Stanczyk, FZ1
Gennari, L1

Reviews

3 review(s) available for lasofoxifene and Atrophy

ArticleYear
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Menopause (New York, N.Y.), 2014, Volume: 21, Issue:3

    Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases

2014
Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:13

    Topics: Atrophy; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vagina; Vaginal Diseases

2009
Lasofoxifene: CP 336156, CP-336156.
    Drugs in R&D, 2005, Volume: 6, Issue:1

    Topics: Adult; Aged; Animals; Atrophy; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Musculoskeletal Diseases; Osteoporosis; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vaginal Diseases

2005